Published in J Biol Chem on June 05, 2007
Membrane transporters in drug development. Nat Rev Drug Discov (2010) 8.56
Toward a systems level understanding of organic anion and other multispecific drug transporters: a remote sensing and signaling hypothesis. Mol Pharmacol (2009) 1.56
Metabolomics reveals signature of mitochondrial dysfunction in diabetic kidney disease. J Am Soc Nephrol (2013) 1.49
What do drug transporters really do? Nat Rev Drug Discov (2014) 1.41
Physiology, structure, and regulation of the cloned organic anion transporters. Xenobiotica (2008) 1.40
Multi-level analysis of organic anion transporters 1, 3, and 6 reveals major differences in structural determinants of antiviral discrimination. J Biol Chem (2008) 1.38
Untargeted metabolomics identifies enterobiome metabolites and putative uremic toxins as substrates of organic anion transporter 1 (Oat1). J Proteome Res (2011) 1.18
Remote communication through solute carriers and ATP binding cassette drug transporter pathways: an update on the remote sensing and signaling hypothesis. Mol Pharmacol (2011) 1.16
Organic anion transporter 3 contributes to the regulation of blood pressure. J Am Soc Nephrol (2008) 1.14
Analysis of three-dimensional systems for developing and mature kidneys clarifies the role of OAT1 and OAT3 in antiviral handling. J Biol Chem (2010) 1.06
A role for the organic anion transporter OAT3 in renal creatinine secretion in mice. Am J Physiol Renal Physiol (2012) 1.02
Interaction of organic cations with organic anion transporters. J Biol Chem (2009) 1.01
The organic anion transporter (OAT) family: a systems biology perspective. Physiol Rev (2015) 1.01
Analysis of a large cluster of SLC22 transporter genes, including novel USTs, reveals species-specific amplification of subsets of family members. Physiol Genomics (2009) 0.93
Linkage of organic anion transporter-1 to metabolic pathways through integrated "omics"-driven network and functional analysis. J Biol Chem (2011) 0.91
Evolutionary Analysis and Classification of OATs, OCTs, OCTNs, and Other SLC22 Transporters: Structure-Function Implications and Analysis of Sequence Motifs. PLoS One (2015) 0.87
Hepatocyte nuclear factors 4α and 1α regulate kidney developmental expression of drug-metabolizing enzymes and drug transporters. Mol Pharmacol (2013) 0.85
Organic anion and cation SLC22 "drug" transporter (Oat1, Oat3, and Oct1) regulation during development and maturation of the kidney proximal tubule. PLoS One (2012) 0.84
Active Hydrophilic Components of the Medicinal Herb Salvia miltiorrhiza (Danshen) Potently Inhibit Organic Anion Transporters 1 (Slc22a6) and 3 (Slc22a8). Evid Based Complement Alternat Med (2012) 0.82
Role of solute carriers in response to anticancer drugs. Mol Cell Ther (2014) 0.81
Shared Ligands Between Organic Anion Transporters (OAT1 and OAT6) and Odorant Receptors. Drug Metab Dispos (2015) 0.81
Analysis of ABCG2 and other urate transporters in uric acid homeostasis in chronic kidney disease: potential role of remote sensing and signaling. Clin Kidney J (2016) 0.81
Implications of the alternating access model for organic anion transporter kinetics. J Membr Biol (2008) 0.80
Growth and development alter susceptibility to acute renal injury. Kidney Int (2008) 0.79
Molecular Properties of Drugs Interacting with SLC22 Transporters OAT1, OAT3, OCT1, and OCT2: A Machine-Learning Approach. J Pharmacol Exp Ther (2016) 0.77
An Organic Anion Transporter 1 (OAT1)-centered Metabolic Network. J Biol Chem (2016) 0.75
Drug-induced Fanconi syndrome associated with fumaric acid esters treatment for psoriasis: a case series. Clin Kidney J (2015) 0.75
The drug transporter OAT3 (SLC22A8) regulates endogenous metabolite flow through the gut-liver-kidney axis. J Biol Chem (2017) 0.75
Renal Drug Transporters and Drug Interactions. Clin Pharmacokinet (2017) 0.75
The Protein Data Bank. Nucleic Acids Res (2000) 187.10
Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. J Am Chem Soc (1988) 6.41
Beware of q2! J Mol Graph Model (2002) 5.13
Decreased renal organic anion secretion and plasma accumulation of endogenous organic anions in OAT1 knock-out mice. J Biol Chem (2005) 2.07
Transport of drugs from the nasal cavity to the central nervous system. Eur J Pharm Sci (2000) 2.01
Volatile signals of the major histocompatibility complex in male mouse urine. Proc Natl Acad Sci U S A (1997) 1.91
Expression cloning and characterization of ROAT1. The basolateral organic anion transporter in rat kidney. J Biol Chem (1997) 1.75
Transport of organic anions across the basolateral membrane of proximal tubule cells. Rev Physiol Biochem Pharmacol (2003) 1.69
Molecular cloning and characterization of NKT, a gene product related to the organic cation transporter family that is almost exclusively expressed in the kidney. J Biol Chem (1997) 1.60
The structural basis of substrate translocation by the Escherichia coli glycerol-3-phosphate transporter: a member of the major facilitator superfamily. Curr Opin Struct Biol (2004) 1.39
FLEXS: a method for fast flexible ligand superposition. J Med Chem (1998) 1.32
The molecular and cellular physiology of basolateral organic anion transport in mammalian renal tubules. Biochim Biophys Acta (2003) 1.30
In vitro and pharmacophore-based discovery of novel hPEPT1 inhibitors. Pharm Res (2005) 1.30
The molecular pharmacology of organic anion transporters: from DNA to FDA? Mol Pharmacol (2004) 1.25
Identification of a novel murine organic anion transporter family member, OAT6, expressed in olfactory mucosa. Biochem Biophys Res Commun (2004) 1.22
Molecular determinants of substrate/inhibitor binding to the human and rabbit renal organic cation transporters hOCT2 and rbOCT2. Mol Pharmacol (2005) 1.21
Ligand conduction and the gated-pore mechanism of transmembrane transport. Biochim Biophys Acta (1997) 1.20
Odorant molecular length: one aspect of the olfactory code. J Comp Neurol (2000) 1.16
Identification of major histocompatibility complex-regulated body odorants by statistical analysis of a comparative gas chromatography/mass spectrometry experiment. Anal Chem (2005) 1.15
Transport of estrone sulfate by the novel organic anion transporter Oat6 (Slc22a20). Am J Physiol Renal Physiol (2006) 1.11
Olfactory mucosa-expressed organic anion transporter, Oat6, manifests high affinity interactions with odorant organic anions. Biochem Biophys Res Commun (2006) 1.06
Intranasal drug delivery for brain targeting. Curr Drug Deliv (2005) 1.04
Molecular requirements of the human nucleoside transporters hCNT1, hCNT2, and hENT1. Mol Pharmacol (2004) 1.02
Renal transporters for organic anions and organic cations. Structural requirements for substrates. J Membr Biol (1997) 0.88
The potential of nasal application for delivery to the central brain-a microdialysis study of fluorescein in rats. Eur J Pharm Sci (2004) 0.88
Cellular and molecular constituents of olfactory sensation in vertebrates. Comp Biochem Physiol A Mol Integr Physiol (2000) 0.86
Contraluminal p-aminohippurate transport in the proximal tubule of the rat kidney. VII. Specificity: cyclic nucleotides, eicosanoids. Pflugers Arch (1991) 0.86
Contraluminal organic anion and cation transport in the proximal renal tubule: V. Interaction with sulfamoyl- and phenoxy diuretics, and with beta-lactam antibiotics. Kidney Int (1989) 0.85
Contraluminal para-aminohippurate (PAH) transport in the proximal tubule of the rat kidney. II. Specificity: aliphatic dicarboxylic acids. Pflugers Arch (1987) 0.81
Contraluminal para-aminohippurate transport in the proximal tubule of the rat kidney. III. Specificity: monocarboxylic acids. Pflugers Arch (1987) 0.79
Contraluminal para-aminohippurate (PAH) transport in the proximal tubule of the rat kidney. IV. Specificity: mono- and polysubstituted benzene analogs. Pflugers Arch (1988) 0.78
Contraluminal p-aminohippurate transport in the proximal tubule of the rat kidney. VIII. Transport of corticosteroids. Pflugers Arch (1991) 0.78
Membrane transporters in drug development. Nat Rev Drug Discov (2010) 8.56
Eya protein phosphatase activity regulates Six1-Dach-Eya transcriptional effects in mammalian organogenesis. Nature (2003) 3.72
Endocytic mechanisms for targeted drug delivery. Adv Drug Deliv Rev (2007) 2.38
Decreased renal organic anion secretion and plasma accumulation of endogenous organic anions in OAT1 knock-out mice. J Biol Chem (2005) 2.07
Impaired organic anion transport in kidney and choroid plexus of organic anion transporter 3 (Oat3 (Slc22a8)) knockout mice. J Biol Chem (2002) 1.87
Impaired Wnt-beta-catenin signaling disrupts adult renal homeostasis and leads to cystic kidney ciliopathy. Nat Med (2009) 1.86
Rapid identification of P-glycoprotein substrates and inhibitors. Drug Metab Dispos (2006) 1.68
Molecular basis of vitamin E action: tocotrienol modulates 12-lipoxygenase, a key mediator of glutamate-induced neurodegeneration. J Biol Chem (2003) 1.61
TGF-beta superfamily members modulate growth, branching, shaping, and patterning of the ureteric bud. Dev Biol (2004) 1.59
Toward a systems level understanding of organic anion and other multispecific drug transporters: a remote sensing and signaling hypothesis. Mol Pharmacol (2009) 1.56
Branching morphogenesis and kidney disease. Development (2004) 1.54
Multiple organic anion transporters contribute to net renal excretion of uric acid. Physiol Genomics (2008) 1.53
Transport of poly(amidoamine) dendrimers across Caco-2 cell monolayers: Influence of size, charge and fluorescent labeling. Pharm Res (2006) 1.51
Identification of interactive gene networks: a novel approach in gene array profiling of myometrial events during guinea pig pregnancy. Am J Obstet Gynecol (2006) 1.50
Spatiotemporal regulation of morphogenetic molecules during in vitro branching of the isolated ureteric bud: toward a model of branching through budding in the developing kidney. Dev Biol (2004) 1.49
Metabolomics reveals signature of mitochondrial dysfunction in diabetic kidney disease. J Am Soc Nephrol (2013) 1.49
Adult kidney tubular cell population showing phenotypic plasticity, tubulogenic capacity, and integration capability into developing kidney. J Am Soc Nephrol (2005) 1.46
Camptothecins: a review of their chemotherapeutic potential. Drugs (2002) 1.40
Human pregnane X receptor antagonists and agonists define molecular requirements for different binding sites. Mol Pharmacol (2007) 1.39
Multi-level analysis of organic anion transporters 1, 3, and 6 reveals major differences in structural determinants of antiviral discrimination. J Biol Chem (2008) 1.38
Design, synthesis, cytoselective toxicity, structure-activity relationships, and pharmacophore of thiazolidinone derivatives targeting drug-resistant lung cancer cells. J Med Chem (2008) 1.37
Surface acetylation of polyamidoamine (PAMAM) dendrimers decreases cytotoxicity while maintaining membrane permeability. Bioconjug Chem (2007) 1.36
A ligand-based approach to identify quantitative structure-activity relationships for the androgen receptor. J Med Chem (2004) 1.35
Microfabricated porous silicon particles enhance paracellular delivery of insulin across intestinal Caco-2 cell monolayers. Pharm Res (2003) 1.34
Topology scanning and putative three-dimensional structure of the extracellular binding domains of the apical sodium-dependent bile acid transporter (SLC10A2). Biochemistry (2004) 1.33
In vitro and pharmacophore-based discovery of novel hPEPT1 inhibitors. Pharm Res (2005) 1.30
The molecular pharmacology of organic anion transporters: from DNA to FDA? Mol Pharmacol (2004) 1.25
Endocytosis and interaction of poly (amidoamine) dendrimers with Caco-2 cells. Pharm Res (2007) 1.25
Changes in gene expression patterns in the ureteric bud and metanephric mesenchyme in models of kidney development. Kidney Int (2003) 1.23
Identification of a novel murine organic anion transporter family member, OAT6, expressed in olfactory mucosa. Biochem Biophys Res Commun (2004) 1.22
Molecular determinants of substrate/inhibitor binding to the human and rabbit renal organic cation transporters hOCT2 and rbOCT2. Mol Pharmacol (2005) 1.21
Endocytosis inhibitors prevent poly(amidoamine) dendrimer internalization and permeability across Caco-2 cells. Mol Pharm (2008) 1.21
Untargeted metabolomics identifies enterobiome metabolites and putative uremic toxins as substrates of organic anion transporter 1 (Oat1). J Proteome Res (2011) 1.18
Remote communication through solute carriers and ATP binding cassette drug transporter pathways: an update on the remote sensing and signaling hypothesis. Mol Pharmacol (2011) 1.16
Pharmacophore-based discovery of ligands for drug transporters. Adv Drug Deliv Rev (2006) 1.15
Glial cell-derived neurotrophic factor independent ureteric bud outgrowth from the Wolffian duct. J Am Soc Nephrol (2007) 1.14
Organic anion transporter 3 contributes to the regulation of blood pressure. J Am Soc Nephrol (2008) 1.14
Current perspectives on the cellular uptake and trafficking of riboflavin. Adv Drug Deliv Rev (2003) 1.13
The solute carrier family 10 (SLC10): beyond bile acid transport. Mol Aspects Med (2013) 1.11
Novel slc22 transporter homologs in fly, worm, and human clarify the phylogeny of organic anion and cation transporters. Physiol Genomics (2004) 1.10
A semimechanistic pharmacokinetic-enzyme turnover model for rifampin autoinduction in adult tuberculosis patients. Antimicrob Agents Chemother (2012) 1.10
Overlapping in vitro and in vivo specificities of the organic anion transporters OAT1 and OAT3 for loop and thiazide diuretics. Am J Physiol Renal Physiol (2008) 1.10
Bias in estimation of transporter kinetic parameters from overexpression systems: Interplay of transporter expression level and substrate affinity. J Pharmacol Exp Ther (2006) 1.10
Rho kinase acts at separate steps in ureteric bud and metanephric mesenchyme morphogenesis during kidney development. Differentiation (2006) 1.08
Beta1-integrin is required for kidney collecting duct morphogenesis and maintenance of renal function. Am J Physiol Renal Physiol (2009) 1.07
Olfactory mucosa-expressed organic anion transporter, Oat6, manifests high affinity interactions with odorant organic anions. Biochem Biophys Res Commun (2006) 1.06
Analysis of three-dimensional systems for developing and mature kidneys clarifies the role of OAT1 and OAT3 in antiviral handling. J Biol Chem (2010) 1.06
Regulation of ureteric bud branching morphogenesis by sulfated proteoglycans in the developing kidney. Dev Biol (2004) 1.05
Cellular entry of G3.5 poly (amido amine) dendrimers by clathrin- and dynamin-dependent endocytosis promotes tight junctional opening in intestinal epithelia. Pharm Res (2010) 1.04
Efflux of depsipeptide FK228 (FR901228, NSC-630176) is mediated by P-glycoprotein and multidrug resistance-associated protein 1. J Pharmacol Exp Ther (2005) 1.04
Toward an etiological classification of developmental disorders of the kidney and upper urinary tract. Kidney Int (2002) 1.04
Membrane topology of human ASBT (SLC10A2) determined by dual label epitope insertion scanning mutagenesis. New evidence for seven transmembrane domains. Biochemistry (2006) 1.03
Analysis of metagene portraits reveals distinct transitions during kidney organogenesis. Sci Signal (2008) 1.03
A role for the organic anion transporter OAT3 in renal creatinine secretion in mice. Am J Physiol Renal Physiol (2012) 1.02
Implications of gene networks for understanding resilience and vulnerability in the kidney branching program. Physiology (Bethesda) (2004) 1.01
Interaction of organic cations with organic anion transporters. J Biol Chem (2009) 1.01
Organic anion and cation transporters occur in pairs of similar and similarly expressed genes. Biochem Biophys Res Commun (2003) 1.01
Comparative pharmacophore modeling of organic anion transporting polypeptides: a meta-analysis of rat Oatp1a1 and human OATP1B1. J Pharmacol Exp Ther (2005) 1.01
Transmembrane domain VII of the human apical sodium-dependent bile acid transporter ASBT (SLC10A2) lines the substrate translocation pathway. Mol Pharmacol (2006) 1.01
Site-directed mutagenesis and use of bile acid-MTS conjugates to probe the role of cysteines in the human apical sodium-dependent bile acid transporter (SLC10A2). Biochemistry (2005) 1.01
Structural determinants of P-glycoprotein-mediated transport of glucocorticoids. Pharm Res (2003) 1.00
Analogs of methyllycaconitine as novel noncompetitive inhibitors of nicotinic receptors: pharmacological characterization, computational modeling, and pharmacophore development. Mol Pharmacol (2007) 1.00
Machine learning methods and docking for predicting human pregnane X receptor activation. Chem Res Toxicol (2008) 0.99
Organic anion transport in choroid plexus from wild-type and organic anion transporter 3 (Slc22a8)-null mice. Am J Physiol Renal Physiol (2003) 0.99
Structural biology and function of solute transporters: implications for identifying and designing substrates. Drug Metab Rev (2002) 0.97
A strategy for in vitro propagation of rat nephrons. Kidney Int (2002) 0.96
Activin A is an endogenous inhibitor of ureteric bud outgrowth from the Wolffian duct. Dev Biol (2006) 0.95
Constructing kidney-like tissues from cells based on programs for organ development: toward a method of in vitro tissue engineering of the kidney. Tissue Eng Part A (2010) 0.95
Computational models to assign biopharmaceutics drug disposition classification from molecular structure. Pharm Res (2007) 0.94
MAPAS: a tool for predicting membrane-contacting protein surfaces. Nat Methods (2008) 0.94
Hs2st mediated kidney mesenchyme induction regulates early ureteric bud branching. Dev Biol (2010) 0.94
Analysis of a large cluster of SLC22 transporter genes, including novel USTs, reveals species-specific amplification of subsets of family members. Physiol Genomics (2009) 0.93
Stage-dependent regulation of mammary ductal branching by heparan sulfate and HGF-cMet signaling. Dev Biol (2011) 0.93
Developmental approaches to kidney tissue engineering. Am J Physiol Renal Physiol (2004) 0.93
G3.5 PAMAM dendrimers enhance transepithelial transport of SN38 while minimizing gastrointestinal toxicity. J Control Release (2010) 0.93
Heregulin induces glial cell line-derived neurotrophic growth factor-independent, non-branching growth and differentiation of ureteric bud epithelia. J Biol Chem (2005) 0.93
Risk factors for development of cholestatic drug-induced liver injury: inhibition of hepatic basolateral bile acid transporters multidrug resistance-associated proteins 3 and 4. Drug Metab Dispos (2013) 0.93
Novel human cDNAs homologous to Drosophila Orct and mammalian carnitine transporters. Biochem Biophys Res Commun (2002) 0.93
The effect of hyaluronic acid size and concentration on branching morphogenesis and tubule differentiation in developing kidney culture systems: potential applications to engineering of renal tissues. Biomaterials (2007) 0.93
Towards a new age of virtual ADME/TOX and multidimensional drug discovery. J Comput Aided Mol Des (2002) 0.93
The developmental nephrome: systems biology in the developing kidney. Curr Opin Nephrol Hypertens (2007) 0.92
Identification and validation of novel human pregnane X receptor activators among prescribed drugs via ligand-based virtual screening. Drug Metab Dispos (2010) 0.92